A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms AESOP
  • Sponsors Intercept Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2017 Results published in a Intercept Pharmaceuticals media release.
    • 31 Jul 2017 Primary endpoint of (Evaluate the effects of obeticholic acid (OCA) on serum alkaline phosphatase (ALP) subjects with Primary Sclerosing Cholangitis (PSC)) has been met.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top